D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients.
coronavirus
fibrinolysis
lung injury
respiratory distress syndrome
thrombosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Dec 2020
24 Dec 2020
Historique:
received:
02
12
2020
revised:
21
12
2020
accepted:
22
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
Host defence mechanisms to counter virus infection include the activation of the broncho-alveolar haemostasis. Fibrin degradation products secondary to extravascular fibrin breakdown could contribute to the marked increase in D-Dimers during COVID-19. We sought to examine the prognostic value on lung injury of D-Dimers in non-critically ill COVID-19 patients without thrombotic events. This study retrospectively analysed hospitalized COVID-19 patients classified according to a D-Dimers threshold following the COVID-19 associated haemostatic abnormalities (CAHA) classification at baseline and at peak (Stage 1: D-Dimers less than three-fold above normal; Stage 2: D-Dimers three- to six-fold above normal; Stage 3: D-Dimers six-fold above normal). The primary endpoint was the occurrence of critical lung injuries on chest computed tomography. The secondary outcome was the composite of in-hospital death or transfer to the intensive care unit (ICU). Among the 123 patients included, critical lung injuries were evidenced in 8 (11.9%) patients in Stage 1, 6 (20%) in Stage 2 and 15 (57.7%) in Stage 3 ( In the absence of overt thrombotic events, D-Dimers quantification is a relevant marker of critical lung injuries and dismal patient outcome.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Host defence mechanisms to counter virus infection include the activation of the broncho-alveolar haemostasis. Fibrin degradation products secondary to extravascular fibrin breakdown could contribute to the marked increase in D-Dimers during COVID-19. We sought to examine the prognostic value on lung injury of D-Dimers in non-critically ill COVID-19 patients without thrombotic events.
METHODS
METHODS
This study retrospectively analysed hospitalized COVID-19 patients classified according to a D-Dimers threshold following the COVID-19 associated haemostatic abnormalities (CAHA) classification at baseline and at peak (Stage 1: D-Dimers less than three-fold above normal; Stage 2: D-Dimers three- to six-fold above normal; Stage 3: D-Dimers six-fold above normal). The primary endpoint was the occurrence of critical lung injuries on chest computed tomography. The secondary outcome was the composite of in-hospital death or transfer to the intensive care unit (ICU).
RESULTS
RESULTS
Among the 123 patients included, critical lung injuries were evidenced in 8 (11.9%) patients in Stage 1, 6 (20%) in Stage 2 and 15 (57.7%) in Stage 3 (
CONCLUSIONS
CONCLUSIONS
In the absence of overt thrombotic events, D-Dimers quantification is a relevant marker of critical lung injuries and dismal patient outcome.
Identifiants
pubmed: 33374487
pii: jcm10010039
doi: 10.3390/jcm10010039
pmc: PMC7795726
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Thromb Res. 2020 Sep;193:166-169
pubmed: 32707275
Chest. 2004 Oct;126(4):1087-92
pubmed: 15486368
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
J Thromb Thrombolysis. 2020 Jul;50(1):54-67
pubmed: 32415579
J Thromb Haemost. 2020 Apr;18(4):786-787
pubmed: 32212240
Thromb J. 2020 Sep 7;18:17
pubmed: 32922211
Am J Respir Crit Care Med. 1996 Jan;153(1):163-7
pubmed: 8542111
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):454-62
pubmed: 10673185
J Thromb Thrombolysis. 2020 Nov;50(4):799-808
pubmed: 32696172
Respiration. 2001;68(2):117-28
pubmed: 11287822
N Engl J Med. 1997 Jan 23;336(4):243-50
pubmed: 8995086
J Clin Invest. 2004 Jul;114(1):104-11
pubmed: 15232617
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
Thromb Res. 2011 Mar;127(3):198-201
pubmed: 21216444
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Clin Med. 2020 May 31;9(6):
pubmed: 32486469
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur Heart J. 2020 Jul 1;41(32):3058-3068
pubmed: 32656565
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2020 Aug;18(8):2075-2076
pubmed: 32470213
Am J Physiol Lung Cell Mol Physiol. 2008 Dec;295(6):L967-75
pubmed: 18836029
J Thromb Haemost. 2015 Jun;13(6):1028-35
pubmed: 25827941
Respir Med. 2020 Jun;167:105941
pubmed: 32421537
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Am J Respir Cell Mol Biol. 1993 Aug;9(2):213-20
pubmed: 8338688
Ann Emerg Med. 2009 May;53(5):633-8
pubmed: 19201061
J Clin Virol. 2020 Jun;127:104362
pubmed: 32305883
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Semin Thromb Hemost. 2008 Jul;34(5):475-84
pubmed: 18956288
Res Pract Thromb Haemost. 2020 Jul 06;4(5):731-736
pubmed: 32685880
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083